@article {Eccles2020.02.21.20025072, author = {Jessica A Eccles and Beth Thompson and Kristy Themelis and Marisa Amato and Robyn Stocks and Amy Pound and Anna-Marie Jones and Zdenka Cipinova and Lorraine Shah-Goodwin and Jean Timeyin and Charlotte R Thompson and Thomas Batty and Neil A Harrison and Hugo D Critchley and Kevin A Davies}, title = {BEYOND BONES - THE RELEVANCE OF VARIANTS OF CONNECTIVE TISSUE (HYPERMOBILITY) TO FIBROMYALGIA, ME/CFS AND CONTROVERSIES SURROUNDING DIAGNOSTIC CLASSIFICATION: AN OBSERVATIONAL STUDY}, elocation-id = {2020.02.21.20025072}, year = {2020}, doi = {10.1101/2020.02.21.20025072}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Objectives To understand the relevance of symptomatic hypermobility and related connective tissue variants to the expression of symptoms in Fibromyalgia and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The study further tested if specific subfactors within the diagnostic classification of hypermobility predict clinical presentations.Design We report part of a larger case-control study exploring mechanisms of chronic pain and fatigue in Fibromyalgia and ME/CFS (https://doi.org/10.1186/ISRCTN78820481)Setting an NHS Clinical Research Facility.Participants A subsample of 87 participants were assessed for symptomatic hypermobility by a trained clinician: 63 presented with a clinical diagnosis of either Fibromyalgia and or ME/CFS confirmed at screening; 24 participants were confirmed as healthy controls.Main outcome measures 1) Brighton Criteria for joint hypermobility syndrome and 2017 hEDS diagnostic criteria. 2) ACR 2010 Diagnostic Criteria for Fibromylagia and Canadian and Fukada diagnostic criteria for ME/CFS. 3) Self report measures of subjective pain, fatigue and interoceptive sensibility.Results Twenty of the 63 patients (32\%) presented with a clinical diagnosis of Fibromyalgia; 24 (38\%) with a clinical diagnosis of ME/CFS and 19 (30\%) with dual diagnoses of fibromyalgia and ME/CFS. After evaluation using clinical research tools, 56 patients (89\%) met ACR diagnostic criteria for fibromyalgia; 59 (94\%) Canadian Criteria for ME/CFS; and 61 (97\%) Fukada Criteria for ME/CFS. After research evaluation 52 patients (85\%) in fact met diagnostic criteria for Fibromyalgia and ME/CFS on all three sets of tools (ACR, Canadian, Fukada). In addition, 51 patients (81\%) and 9 (37.5\%) healthy controls met Brighton Criteria for joint hypermobility syndrome and 11 (18\%) and 2 (8\%) of patients and controls respectively, on the 2017 hEDS criteria. Of these patient participants with symptomatic hypermobility only 12 (23.5\%) had received a prior diagnosis of hypermobility.Across all participants meeting Brighton Criteria, 13 (22\%) also endorsed a hEDS diagnosis. Membership of the patient group was predicted by meeting the Brighton Criteria for joint hypermobility syndrome (p=\<0.001, OR 7.08, 95\%CI 2.50 {\textendash} 20.00), but not by meeting the hEDS criteria. The historical, rather than current Beighton score correlated with; 1) total pain reported on the McGill Pain Questionnaire (short form), (r= 0.25, n= 73, p=0.03); 2) Widespread Pain Index (derived from ACR diagnostic criteria) (r=0.26, n= 86, p=0.01); 3) ACR symptom severity (r=0.27, n=85, p=0.01); 4) Fatigue Impact (r=0.29, n=56, p=0.28); and 5) interoceptive sensibility (r=0.30, n=56, p=0.02).Conclusions Symptomatic joint hypermobility is relevant to symptoms and diagnosis in Fibromyalgia and ME/CFS. These conditions are poorly understood yet have a considerable impact on quality of life. Further work is needed to determine the prevalence of hEDS within the general population and define the critical clinical dimensions within symptomatic hypermobility. It is important to note the high rates of mis/underdiagnosis of symptomatic hypermobility in this group. Moreover, we need to clarify the role of variant connective tissue in dysautonomic and inflammatory mechanisms implicated in the expression of pain and fatigue in fibromyalgia and ME/CFS. Our observations have implications for diagnosis and treatment targets.Study registration ISCRTN78820481Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://doi.org/10.1186/ISRCTN78820481 Funding StatementThis project was primarily funded by a Versus Arthritis Grant (21994), with additional support provided by a studentship awarded by Action for M.E. and match-funded by Brighton and Sussex Medical School. The work was also supported by a charitable donation from the Fibroduck Foundation. Jessica Eccles was supported by the National Institute of Health Research (CL-2015-27-002).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeindentified participant data is available upon reasonable request from the corresponding author (ORCID ID https://orcid.org/0000-0002-0062-1216).}, URL = {https://www.medrxiv.org/content/early/2020/02/23/2020.02.21.20025072}, eprint = {https://www.medrxiv.org/content/early/2020/02/23/2020.02.21.20025072.full.pdf}, journal = {medRxiv} }